» Articles » PMID: 34439332

Ovarian Cancer and Cancer Stem Cells-Cellular and Molecular Characteristics, Signaling Pathways, and Usefulness As a Diagnostic Tool in Medicine and Oncology

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Aug 27
PMID 34439332
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the increasing development of medicine, ovarian cancer is still a high-risk, metastatic disease that is often diagnosed at a late stage. In addition, difficulties in its treatment are associated with high resistance to chemotherapy and frequent relapse. Cancer stem cells (CSCs), recently attracting significant scientific interest, are considered to be responsible for the malignant features of tumors. CSCs, as the driving force behind tumor development, generate new cells by modifying different signaling pathways. Moreover, investigations on different types of tumors have shown that signaling pathways are key to epithelial-mesenchymal transition (EMT) regulation, metastasis, and self-renewal of CSCs. Based on these established issues, new therapies are being investigated based on the use of inhibitors to block CSC growth and proliferation signals. Many reports indicate that CSC markers play a key role in cancer metastasis, with hopes placed in their targeting to block this process and eliminate relapses. Current histological classification of ovarian tumors, their epidemiology, and the most recent knowledge of ovarian CSCs, with particular emphasis on their molecular background, are important aspects for consideration. Furthermore, the importance of signaling pathways involved in tumor growth, development, and metastasis, is also presented.

Citing Articles

Cancer stem cells and tumor-associated macrophages as mates in tumor progression: mechanisms of crosstalk and advanced bioinformatic tools to dissect their phenotypes and interaction.

Verona F, Di Bella S, Schirano R, Manfredi C, Angeloro F, Bozzari G Front Immunol. 2025; 16:1529847.

PMID: 39981232 PMC: 11839637. DOI: 10.3389/fimmu.2025.1529847.


Molecular pathways in reproductive cancers: a focus on prostate and ovarian cancer.

Ajayi A, Oyovwi M, Akano O, Akanbi G, Adisa F Cancer Cell Int. 2025; 25(1):33.

PMID: 39901204 PMC: 11792371. DOI: 10.1186/s12935-025-03658-5.


Exploring the Shared Pathogenesis Mechanisms of Endometriosis and Cancer: Stemness and Targeted Treatments of Its Molecular Pathways-A Narrative Review.

Mitranovici M, Costachescu D, Voidazan S, Munteanu M, Buicu C, Oala I Int J Mol Sci. 2024; 25(23).

PMID: 39684461 PMC: 11640855. DOI: 10.3390/ijms252312749.


overexpression stimulates cell proliferation and is predictive of poor outcome in ovarian cancer.

Jin W, Hui H, Jiang J, Li B, Deng Z, Tuo X Transl Cancer Res. 2024; 13(10):5265-5277.

PMID: 39525021 PMC: 11543041. DOI: 10.21037/tcr-24-430.


Ovarian cancer ascites proteomic profile reflects metabolic changes during disease progression.

Almeida-Nunes D, Nunes M, Osorio H, Ferreira V, Lobo C, Monteiro P Biochem Biophys Rep. 2024; 39:101755.

PMID: 38974022 PMC: 11225207. DOI: 10.1016/j.bbrep.2024.101755.


References
1.
Shih I, Kurman R . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004; 164(5):1511-8. PMC: 1615664. DOI: 10.1016/s0002-9440(10)63708-x. View

2.
Desai A, Xu J, Aysola K, Qin Y, Okoli C, Hariprasad R . Epithelial ovarian cancer: An overview. World J Transl Med. 2014; 3(1):1-8. PMC: 4267287. DOI: 10.5528/wjtm.v3.i1.1. View

3.
Bocchicchio S, Tesone M, Irusta G . Convergence of Wnt and Notch signaling controls ovarian cancer cell survival. J Cell Physiol. 2019; 234(12):22130-22143. DOI: 10.1002/jcp.28775. View

4.
Sabol M, Car D, Musani V, Ozretic P, Oreskovic S, Weber I . The Hedgehog signaling pathway in ovarian teratoma is stimulated by Sonic Hedgehog which induces internalization of Patched. Int J Oncol. 2012; 41(4):1411-8. DOI: 10.3892/ijo.2012.1554. View

5.
Fujiwara K, Shintani D, Nishikawa T . Clear-cell carcinoma of the ovary. Ann Oncol. 2016; 27 Suppl 1:i50-i52. DOI: 10.1093/annonc/mdw086. View